Revolutionary AI Algorithm ‘Prostate.Carcinoma.ai’ Achieves EU MDR Class IIa Certification

By /

Xlife Sciences AG (SIX: XLS) witnesses a landmark achievement for medical technology in the portfolio company FUSE-AI GmbH.

Scroll to Top